SG Americas Securities LLC Acquires 1,015,775 Shares of CVS Health Corporation $CVS

Key Points

• SG Americas Securities LLC boosted its stake in CVS by 1,575.7% in Q4, buying 1,015,775 shares to hold 1,080,242 shares (about 0.09% of the company) valued at roughly $85.73 million.
• A proposed FTC settlement over insulin pricing for Caremark and analyst upgrades (including Bernstein's move to Outperform) have eased legal uncertainty and helped lift investor sentiment toward CVS.
• CVS recently beat quarterly estimates (EPS $1.09 vs. $1.00; revenue $105.69B vs. $103.67B), set FY2026 guidance of $5.94–$6.14 EPS, and announced a $0.665 quarterly dividend (annualized yield ~3.7%).

SG Americas Securities LLC grew its stake in shares of CVS Health Corporation (NYSE:CVS - Free Report) by 1,575.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,080,242 shares of the pharmacy operator's stock after buying an additional 1,015,775 shares during the period. SG Americas Securities LLC owned 0.09% of CVS Health worth $85,728,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the stock. Harbor Capital Advisors Inc. boosted its position in shares of CVS Health by 72.1% during the third quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator's stock worth $26,000 after acquiring an additional 142 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after acquiring an additional 281 shares during the last quarter. Corundum Trust Company INC purchased a new stake in CVS Health in the 3rd quarter worth $29,000. Front Row Advisors LLC boosted its holdings in shares of CVS Health by 436.5% during the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator's stock valued at $31,000 after purchasing an additional 371 shares during the last quarter. Finally, GoalVest Advisory LLC purchased a new position in shares of CVS Health during the fourth quarter valued at about $32,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Proposed FTC settlement on insulin pricing for Caremark eases a major legal overhang — CVS said it reached a proposed agreement with FTC staff covering its Caremark PBM unit (Caremark denies wrongdoing). The resolution reduces uncertainty around potential fines or structural remedies that could have been disruptive to PBM operations, and was the main constructive catalyst for the rally. CVS reaches insulin pricing settlement with FTC
• Positive Sentiment: Analyst upgrade supports sentiment — Bernstein upgraded CVS to Outperform (price target raised to ~$94), highlighting exposure to a Medicare Advantage turnaround and improving fundamentals; upgrades can draw buying interest from institutional investors. Bernstein Upgrades CVS Health (CVS) Stock to Outperform from Market Perform
• Neutral Sentiment: Health-care sector breadth provided tailwinds — the NYSE Health Care Index rose late in the session, lifting peers and creating a supportive macro backdrop for CVS. Sector momentum likely amplified the stock's move. Sector Update: Health Care Stocks Advance Late Afternoon
• Neutral Sentiment: Technical bounce after multi-session weakness — coverage noted CVS rising after a six-session losing streak, which can attract short-term buyers and traders looking for mean reversion. CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
• Negative Sentiment: State-level political pressure could create regulatory risk — reporting shows a Tennessee bill that would pit retail pharmacies against PBMs (potentially forcing CVS to choose between its stores and Caremark), and a local report flagged ~$479M in related spending; this raises the prospect of restrictive state laws or reputational risk. This bill could make CVS choose between its stores and its pharmacy benefit manager
• Negative Sentiment: Political/legal headline noise and potential compliance issues — coverage of CVS spending >$1M on ads to oppose the pharmacy bill and reporting that Tenn. AG says certain company texts could violate state law add short-term political and legal uncertainty that could pressure sentiment if escalated. CVS Health spends more than $1M on TV ads to block pharmacy bill Tenn. AG: CVS texts on pharmacy bill could violate state law
• Negative Sentiment: Critical articles highlight operational and valuation risks — some media pieces calling out risks in CVS’ business mix and recent share declines can reinforce cautious positioning among investors. 3 Reasons CVS is Risky and 1 Stock to Buy Instead

Analyst Upgrades and Downgrades

CVS has been the topic of a number of research analyst reports. Wolfe Research decreased their target price on CVS Health from $100.00 to $97.00 and set an "outperform" rating on the stock in a research report on Monday, March 2nd. JPMorgan Chase & Co. raised their price target on CVS Health from $93.00 to $101.00 and gave the company an "overweight" rating in a report on Wednesday, December 17th. Argus decreased their price objective on CVS Health from $91.00 to $90.00 and set a "buy" rating on the stock in a report on Wednesday, January 28th. Barclays increased their target price on CVS Health from $87.00 to $93.00 and gave the company an "overweight" rating in a research report on Wednesday, December 10th. Finally, Robert W. Baird raised their target price on shares of CVS Health from $82.00 to $92.00 and gave the company an "outperform" rating in a report on Wednesday, December 10th. Twenty investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $95.05.

CVS Health Trading Up 2.1%

CVS opened at $72.80 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.63 and a current ratio of 0.84. The stock's 50 day moving average price is $77.14 and its 200-day moving average price is $77.81. CVS Health Corporation has a one year low of $58.35 and a one year high of $85.15. The stock has a market cap of $92.61 billion, a price-to-earnings ratio of 52.75, a P/E/G ratio of 0.74 and a beta of 0.49.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.00 by $0.09. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a return on equity of 11.31% and a net margin of 0.44%.CVS Health's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period last year, the company earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. On average, equities analysts forecast that CVS Health Corporation will post 5.89 EPS for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.7%. The ex-dividend date of this dividend is Thursday, April 23rd. CVS Health's payout ratio is currently 192.75%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.